Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc...

Area of Science:

• Hematology
• Oncology
• Patient-Reported Outcomes

Background:

• Myelofibrosis (MF) significantly impacts patient quality of life (QoL) and symptom burden, particularly when complicated by anemia.
• The specific effects of transfusion burden and anemia severity on MF patient QoL remain incompletely understood.

Purpose of the Study:

• To explore the association between transfusion status, hemoglobin improvement, and patient-reported outcomes (PROs) in myelofibrosis patients.
• To characterize the impact of anemia management on QoL and symptoms in MF.

Main Methods:

• Post hoc analysis of pooled data from three clinical trials (SIMPLIFY-1, SIMPLIFY-2, MOMENTUM).
• Evaluation of patient-reported outcomes including SF-36v2, EORTC QLQ-C30, EQ-5D-5L, PGIC, and MPN-SAF/MFSAF Total Symptom Score.
• Analysis focused on transfusion independence and hemoglobin level changes from baseline to week 24.

Main Results:

• Patients achieving transfusion independence demonstrated numerically greater QoL scores (SF-36v2, EORTC QLQ-C30) compared to transfusion-dependent patients.
• MF patients who became transfusion independent at week 24 showed greater PRO improvements than those remaining transfusion-dependent.
• Hemoglobin improvement (≥1, ≥1.5, or ≥2 g/dL) correlated with clinically meaningful improvements in QoL and symptoms, irrespective of transfusion status.

Conclusions:

• Transfusion status and anemia severity are associated with QoL in myelofibrosis patients.
• Current PRO measures may not fully capture the complex relationship between anemia, fatigue, and QoL in MF.
• Development of novel PRO measures is suggested to better assess the patient experience in anemic MF populations.